Shimakura Kuniyoshi, Miura Hironori, Ikeda Kaori, Ishizaki Shoichiro, Nagashima Yuji, Shirai Toshihiro, Kasuya Shiro, Shiomi Kazuo
Department of Food Science and Technology, Faculty of Marine Science, Tokyo University of Marine Science and Technology, Minato-ku, Tokyo 108-8477, Japan.
Mol Biochem Parasitol. 2004 May;135(1):69-75. doi: 10.1016/j.molbiopara.2004.01.007.
A heat-stable allergen with a molecular weight of 21 k was purified from larvae of the nematode Anisakis simplex by gel filtration, anion-exchange FPLC and reverse-phase HPLC. When analyzed by immunoblotting and ELISA, seven of eight patient sera reacted to the 21 k allergen, demonstrating that this protein is a major allergen of A. simplex. A full-length cDNA encoding the 21 k allergen was cloned by a combination of 3'RACE and screening of an expression library with DIG-labeled DNA probes. The precursor of the 21 k allergen was judged to be composed of a signal peptide (23 residues) and a mature protein (171 residues). As compared to the N-terminal amino acid sequence (up to the 17th residue) of Ani s 1 previously identified as the major allergen, the 21 k allergen has only one replacement, suggesting that the 21 k allergen belongs to the same protein family of Ani s 1. Although the 21 k allergen was found to have 30-40% sequence identity with Kunitz-type trypsin inhibitor domain containing hypothetical proteins of Caenorhabditis elegans, it lacked inhibitory activity against trypsin. The 21 k allergen was successfully expressed in Escherichia coli as a GST-fusion protein showing reactivity with IgE in patient sera.
通过凝胶过滤、阴离子交换快速蛋白质液相色谱法(FPLC)和反相高效液相色谱法(HPLC),从简单异尖线虫幼虫中纯化出一种分子量为21k的热稳定变应原。通过免疫印迹法和酶联免疫吸附测定(ELISA)分析时,8份患者血清中有7份与21k变应原发生反应,表明该蛋白是简单异尖线虫的主要变应原。通过3'端快速扩增cDNA末端(3'RACE)和用DIG标记的DNA探针筛选表达文库相结合的方法,克隆了编码21k变应原的全长cDNA。判断21k变应原的前体由一个信号肽(23个残基)和一个成熟蛋白(171个残基)组成。与先前鉴定为主要变应原的Ani s 1的N端氨基酸序列(至第17个残基)相比,21k变应原只有一个替换,表明21k变应原属于Ani s 1的同一蛋白家族。尽管发现21k变应原与秀丽隐杆线虫含Kunitz型胰蛋白酶抑制剂结构域的假设蛋白具有30%-40%的序列同一性,但它对胰蛋白酶缺乏抑制活性。21k变应原在大肠杆菌中成功表达为一种谷胱甘肽S-转移酶(GST)融合蛋白,该融合蛋白与患者血清中的IgE发生反应。